Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug therapy, nipocalimab, met its primary endpoint and multiple key secondary ...
Ribupatide (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg ...
Janus kinase (JAK) inhibitors, including baricitinib, block cytokine signaling and are effective disease-modifying treatments for several autoimmune diseases. Whether baricitinib preserves β-cell ...
Andrew Nixon, spokesman for Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., announced on Thursday that moving forward, “all new vaccines will undergo safety testing in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results